Management of corticosteroid-dependent eosinophilic interstitial nephritis: A case report. 2021

Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

BACKGROUND Drug-induced acute interstitial nephritis (DI-AIN) is an important cause of acute kidney injury. In renal biopsy specimens, tubulitis with eosinophilic infiltration is suggestive of DI-AIN. Although corticosteroid therapy and discontinuation of the offending drug can improve renal dysfunction in most cases of DI-AIN, some patients experience AIN recurrence, leading to corticosteroid dependency. Corticosteroid-dependent eosinophilic interstitial nephritis presents a difficult dilemma in diagnosis and information regarding optimum management is limited. METHODS A 25-year-old man, who received treatment with carbamazepine, zonisamide, valproate, and lacosamide for temporal lobe epilepsy, showed an increase in serum creatinine level from 0.98 to 1.29 mg/dL over a period of 6 months. Although he exhibited no symptoms, his serum creatinine level continued to increase to 1.74 mg/dL. METHODS Renal biopsy revealed tubulitis and interstitial inflammatory infiltrates with eosinophils. Immunological and ophthalmological examinations showed no abnormal findings, and thus, his renal dysfunction was presumed to be caused by DI-AIN. Although oral prednisolone (PSL) administration (40 mg/d) and discontinuation of zonisamide immediately improved his renal function, AIN recurred 10 months later. The increase in PSL dose along with discontinuation of valproate and lacosamide improved renal function. However, 10 months later, recurrent AIN with eosinophilic infiltration was confirmed by further biopsy. The patient was therefore diagnosed with corticosteroid-dependent eosinophilic interstitial nephritis. METHODS To prevent life-threatening epilepsy, carbamazepine could not be discontinued; hence, he was treated with an increased dose of PSL (60 mg/d) and 1500 mg/d of mycophenolate mofetil (MMF). RESULTS MMF was well tolerated and PSL was successfully tapered to 5 mg/d; renal function stabilized over a 20-month period. CONCLUSIONS The presence of underdetermined autoimmune processes and difficulties in discontinuing the putative offending drug discontinuation are contributing factors to corticosteroid dependency in patients with eosinophilic interstitial nephritis. MMF may be beneficial in the management of corticosteroid-dependent eosinophilic interstitial nephritis by reducing the adverse effects related to high-dose and long-term corticosteroid use.

UI MeSH Term Description Entries
D008297 Male Males
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D009395 Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction. Interstitial Nephritis,Nephritis, Tubulointerstitial,Tubulointerstitial Nephritis,Interstitial Nephritides,Nephritides, Interstitial,Nephritides, Tubulointerstitial,Tubulointerstitial Nephritides
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078305 Zonisamide A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization. 3-Sulfamoylmethyl-1,2-benzisoxazole,AD 810,AD-810,CI 912,CI-912,Zonegran,Zonisamide Monosodium,3 Sulfamoylmethyl 1,2 benzisoxazole,AD810,CI912
D000078334 Lacosamide An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES. N-benzyl-2-acetamido-3-methoxypropionamide,N-benzyl-AcMeOPrNH2,Vimpat,N benzyl 2 acetamido 3 methoxypropionamide,N benzyl AcMeOPrNH2
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
November 1979, Clinical immunology and immunopathology,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
August 1976, Indian pediatrics,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
June 2021, BMC nephrology,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
November 1999, Pediatric nephrology (Berlin, Germany),
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
January 1986, Indian journal of pathology & microbiology,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
December 2019, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
May 1979, AMB : revista da Associacao Medica Brasileira,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
April 1971, The Indian veterinary journal,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
December 1994, Minerva pediatrica,
Katsuyuki Tanabe, and Natsumi Matsuoka-Uchiyama, and Tomoyo Mifune, and Chieko Kawakita, and Hitoshi Sugiyama, and Jun Wada
January 1998, La Pediatria medica e chirurgica : Medical and surgical pediatrics,
Copied contents to your clipboard!